MARKET

PTE

PTE

PolarityTE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9742
+0.0531
+5.76%
After Hours: 0.9400 -0.0342 -3.51% 19:37 05/07 EDT
OPEN
0.9100
PREV CLOSE
0.9211
HIGH
0.9824
LOW
0.9100
VOLUME
838.39K
TURNOVER
--
52 WEEK HIGH
2.380
52 WEEK LOW
0.5530
MARKET CAP
78.51M
P/E (TTM)
-0.8610
1D
5D
1M
3M
1Y
5Y
PolarityTE, Inc. (PTE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Zacks.com · 5d ago
PolarityTE to Report First Quarter Financial Results on May 13, 2021
PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the quarter ended March 31, 2021 by press release on Thursday, May 13, 2021 at approximately 4:00 p.m. Eastern Time.
Business Wire · 5d ago
Northland Securities Maintains Their Buy Rating on PolarityTE (PTE)
In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on PolarityTE (PTE), with a price target of $3.00. The company's
SmarterAnalyst · 04/28 11:05
Is the Options Market Predicting a Spike in PolarityTE (PTE) Stock?
Zacks.com · 04/07 20:05
H.C. Wainwright Keeps Their Hold Rating on PolarityTE (PTE)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Hold rating on PolarityTE (PTE) today. The company's shares closed last Tuesday at $1.21.
SmarterAnalyst · 03/31 10:26
DJ PolarityTE, Inc. CEO David Seaburg on Q4 2020 Results -- Earnings Call Transcript >PTE
Dow Jones · 03/30 16:02
Gold Fields, Danimer Scientific among premarket losers' pack
AeroCentury (ACY) -46% after filing petition for Chapter 11Wave Life Sciences (WVE) -27% on setback for Huntington’s disease trial (updated).Trxade Group (MEDS) -21% on Q4 earnings release.Vinco Ventures (BBIG) -16% on providing update to ZASH Global Media...
Seekingalpha · 03/30 12:42
The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 29)
Benzinga · 03/30 12:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PTE. Analyze the recent business situations of PolarityTE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PTE stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 112
Institutional Holdings: 11.77M
% Owned: 14.61%
Shares Outstanding: 80.59M
TypeInstitutionsShares
Increased
12
866.87K
New
12
2.77M
Decreased
12
877.71K
Sold Out
7
252.00K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Independent Director
Peter Cohen
President/Chief Operating Officer
Richard Hague
Chief Executive Officer/Director
David Seaburg
Chief Financial Officer
Jacob Patterson
Executive Vice President/General Counsel/Secretary
Cameron Hoyler
Director
Chris Nolet
Vice President
Sharon Whalen
Director
Jessica Shen
Director
Jay Hood
Independent Director
Minnie Baylor-Henry
Independent Director
Willie Bogan
Independent Director
Jeff Dyer
Declaration Date
Dividend Per Share
Ex-Div Date
01/04/2016
Dividend USD 0.33550232
01/19/2016
About PTE
PolarityTE, Inc., formerly Majesco Entertainment Company, is the owner of patent applications and know-how related to regenerative medicine and tissue engineering, as well as software applications used in diagnosis and treatment related to regenerative medicine. The Company seeks to develop and obtain regulatory approval for technology that will utilize a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. The Company's PolarityTE platform simplifies regeneration and allows cells to function naturally. The platform can be applied across all cells, tissues and composite structures. The Company focuses on various products, including SkinTE, OsteoTE, AngioTE, MyoTE, CartTE, AdiposeTE and NeuralTE. The Company, through SkinTE, is focused on supplying an autologous construct to regenerate a patient’s skin due to a variety of injuries and conditions.

Webull offers kinds of Polarityte Inc stock information, including NASDAQ:PTE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTE stock methods without spending real money on the virtual paper trading platform.